CORMEDIX INC. DL-,001

CorMedix reported Q2 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, driven by DefenCath sales and the acquired Melinta portfolio. The company reaffirmed full-year revenue guidance of $325–345 million and raised adjusted EBITDA guidance to $125–140 million, ending the quarter with $256.7 million in cash. CorMedix signed a multi-year DefenCath supply agreement with an additional large dialysis organization, bringing contracts with all five top U.S. providers, and plans pilot rollout in Q3. Management expects Mundipharma to submit an sNDA for REZZAYO prophylaxis in Q3 based on positive Phase III ReSPECT data, with potential FDA action in H1 2027, and is preparing commercial hires and modest incremental spend for a possible launch. » Plus sur finance.yahoo.com

CorMedix reported adjusted earnings of $0.29 per share for Q2 2026 on revenue of $101.9 million, beating analyst estimates. The company raised its adjusted EBITDA guidance for 2026 to $125–140 million, reported strong growth from DefenCath and the Melinta portfolio, and secured new supply contracts with all five leading US dialysis providers. The stock rose sharply premarket; management announced pilot programs and key regulatory milestones for REZZAYO but warned of reimbursement and customer-concentration risks. » Plus sur de.investing.com

The U.S. District Court for New Jersey granted preliminary approval for the proposed settlement in the consolidated shareholder derivative action against CorMedix (In re CorMedix Inc. Derivative Litigation; related case Raval v. Baluch). A final fairness hearing to approve the settlement is scheduled for September 23, 2026. CorMedix filed the necessary papers in an SEC filing; at the same time the company reported strong Q1 2026 revenue of $127.4 million with a slight EPS miss of $0.43. A federal appeals court also previously upheld the validity of patents for MINOCIN for Injection, marking a victory against Nexus Pharmaceuticals. » Plus sur de.investing.com

CorMedix posted Q1 2026 net revenue of $127.4 million, net income of $38.6 million and adjusted EBITDA of $70.0 million. DefenCath contributed $97.5 million in revenue, aided by higher outpatient dialysis use and a $9.0 million favorable estimate change, while the acquired Melinta portfolio added $29.9 million. The company raised 2026 guidance to $325–$345 million in revenue and $115–$135 million in adjusted EBITDA and reported $178.1 million in cash and short-term investments as of March 31, 2026. Management said DefenCath is exceeding expectations and highlighted progress in late-stage programs including REZZAYO, with an FDA submission planned for H2 2026 and a potential expanded launch in 2027. » Plus sur finance.yahoo.com

CorMedix reported revenue of $127.4 million for Q1 2026, significantly beating expectations, while earnings per share of $0.43 were slightly below the $0.45 forecast. Revenue growth of 226% year‑over‑year was driven largely by demand for DefenCath and the acquisition of Melinta. The company raised its full‑year revenue and adjusted EBITDA guidance (revenue now $325–345 million, adjusted EBITDA $115–135 million). As a result, the stock rose about 13.5% in premarket trading and market sentiment was positive. » Plus sur de.investing.com